PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer (Pfizer)
- Oshi Health’s 2025 Impact Report Demonstrates Exceptional GI Outcomes and Cost Savings at Scale (PR Newswire)
- Medtronic announces CE Mark for the next generation GI Genius™ module and ColonPRO™ software (Medtronic)
- Allurion gets FDA nod for weight loss balloon (Mass Device)
- The 7 Must-Haves For The Doctor Of the 21st Century (The Medical Futurist)
- Will AI Eventually De-Skill Doctors? The Evidence Is Trickling In (Forbes)
- CRC Screening by Colonoscopy and FIT Improves Early Detection over Usual Care (Inside Precision Medicine)
- It’s Called the ‘Fitbit for Farts’—and It’s No Joke (The Wall Street Journal)
